A population based clinical and molecular genetic study of familial adenomatous polyposis coli (FAPC) was performed to investigate the value of molecular genetic analysis and ophthalmological assessment in the presymptomatic diagnosis of FAPC. The point prevalence of affected patients was 2-62 x 10-5 (1/38 000) and the minimum heterozygote prevalence was estimated at 3-8 x 10-5 (1/26 000). Eight of 33 (24%) probands were new mutations. Fortyeight asymptomatic relatives at 50% prior risk aged between 10 and 40 years were assessed for risk modification with linked DNA markers: in nine subjects (18%) the family structure was unsuitable for linkage based analysis, but 32 subjects were informative with a panel of intragenic and closely linked markers (25 had a combined age/DNA related risk of < 1% (low risk group) and seven were at high risk (DNA predicted risk >99%)). Ophthalmological assessment for CHRPEs showed that 27/43 (63%) affected patients and high risk relatives and 0/ 18 low risk relatives had more than three CHRPEs. Interfamilial variation in CHRPE expression was apparent. This study has shown that DNA based risk modification with intragenic and closely linked DNA markers is informative in most FAPC families. In addition to the clinical benefits of presymptomatic diagnosis for FAPC, the reduction in screening for low risk relatives (365 person years in the present study) means that molecular genetic diagnosis of FAPC is a cost effective procedure. (J Med Genet 1993;30:675-8) Familial adenomatous polyposis coli (FAPC) is a dominantly inherited disorder characterised by the development of numerous (at least 100) colorectal polyps. Age at onset is variable, but polyps usually develop in teenage years and penetrance is almost complete at the age of 40 
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GENETIC LINKAGE ANALYSIS
Twenty-two of 26 kindreds had a suitable structure for linkage based risk modification. These kindreds contained 39 subjects at 50% prior risk aged between 10 and 40 years and 38 of these requested investigation for risk modification by linked DNA markers. After molecular investigation with the protocol described previously, 32 relatives were informative, three are still being studied, and DNA testing did not significantly alter the risk of three subjects (figure). The three uninformative subjects (Si, TI, and T2) were from two families in which the family structure was not optimal for linkage based analysis. In CHRPEs who was at low risk with flanking DNA markers (Pi227 and YN5.48). CHRPE analysis provides a method of independently confirming the results of molecular genetic analysis, but further studies are needed to determine the molecular basis for interfamilial differences in the frequency of CHRPEs.
COST-BENEFIT ANALYSIS
We have not attempted to perform a detailed cost-benefit analysis of our programme (such an analysis would have to quantify the benefit of reassuring at risk relatives as well as the prevention of colorectal cancers, etc); however, it is possible to estimate the reduction in screening produced by identifying low risk subjects. We estimate that by discontinuing screening in the 25 low risk relatives we will avoid 365 person years of unnecessary screening. The cost of a single colonoscopy has been estimated as /107,28 so for a screening programme based on three yearly colonoscopy (the most frequently used protocol in East Anglia), a saving of 365 person years translates into a future financial saving of approximately £13 000 at current costing.
